"The renal glomerular capillaries reflect the arterial changes in systemic vasculature... microalbuminuria is a window to vascular health," says Dr. Anil Pareek in an insightful conversation with Dr. P.C. Manoria at the World Congress Cardio Kidney Metabolic (WC CKM) Medicine 2026. In this interview, Dr. Pareek discusses the evolution from Metabolic Syndrome to the modern CKM (Cardio-Kidney-Metabolic) framework, advocating for the inclusion of the liver (CKLM) and the critical role of the Urine Albumin-Creatinine Ratio (UACR) as a red flag for cardiovascular risk. Top 5 Takeaways from the Conversation: 1 CKLM over CKM: Adding "Liver" (CKLM) is vital because liver fat is a primary driver of metabolic dysfunction and visceral obesity. 2 The Vascular Window: Microalbuminuria isn't just a kidney marker; it’s a direct "window" into the health of your entire arterial system. 3 The 10 mg/g Rule: Heart risk doesn't start at the 30 mg/g "cutoff"—it begins to spike significantly as soon as levels hit 10 mg/g. 4 UACR is King: Don't wait for Serum Creatinine to rise; by then, damage is done. UACR is the superior tool for early detection. 5 Aggressive Triple Therapy: Combining RAS blockers, SGLT2 inhibitors, and MRAs can slash albuminuria by over 50% for maximum protection. Dr. Anil Pareek is the President of Medical Affairs and Clinical Research at Ipca Laboratories Limited. He is a renowned expert in clinical research and the pharmacological management of metabolic and cardiovascular diseases. Dr. P.C. Manoria is the Executive President for the World Congress Cardio Kidney Metabolic (WC CKM) Medicine and a distinguished cardiologist known for his leadership in integrating multi-organ care.